NO975080L - Inhibitorer av fibrintverrbinding og/eller transglutaminaser - Google Patents

Inhibitorer av fibrintverrbinding og/eller transglutaminaser

Info

Publication number
NO975080L
NO975080L NO975080A NO975080A NO975080L NO 975080 L NO975080 L NO 975080L NO 975080 A NO975080 A NO 975080A NO 975080 A NO975080 A NO 975080A NO 975080 L NO975080 L NO 975080L
Authority
NO
Norway
Prior art keywords
pro
inhibitors
leu
lys
sequence
Prior art date
Application number
NO975080A
Other languages
English (en)
Other versions
NO975080D0 (no
Inventor
Roy T Sawyer
Robert B Wallis
Lisa Seale
Sarah Finney
Original Assignee
Biopharm Research & Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopharm Research & Dev Ltd filed Critical Biopharm Research & Dev Ltd
Publication of NO975080D0 publication Critical patent/NO975080D0/no
Publication of NO975080L publication Critical patent/NO975080L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Inhibitorene, som kan oppnås fra vev eller sekreter av blodigler typisk av ordenen Rhynchobdellida, har følgende terminalsekvens: NH2-Lys-Leu-Leu-Pro-Cys-Lys-Glu-Y-His-Gln-Gly-Ile-Pro-Asn-Pro-Arg- hvor Y representerer en hvilken som helst aminosyresekvens; eller et farmasøytisk akseptabelt salt, derivat eller bioforløper av nevnte sekvens, eller en analog eller homolog derav. På grunn av deres ekstreme virkningsgrad i det nanomolare området kan de anvendes for behandling av en rekke sykdommer der proteintverrbinding er viktig. De kan anvendes for behandling av Crohn's sykdom tumorimplantasjon, atero sklerose, trombotisk mikroangiopati, fibrøse vekster i huden, åene, arrdannelse, membranøs glomerulonefritt, katarakter, eller infeksjon med mikrofilareale nematoder. De kan spesielt anvendes for å redusere stabiliteten av tromber slik at de er mer mottakelige for lysering med trombolytiske midler.
NO975080A 1995-05-05 1997-11-04 Inhibitorer av fibrintverrbinding og/eller transglutaminaser NO975080L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9509271.4A GB9509271D0 (en) 1995-05-05 1995-05-05 Blood clot stabilisation inhibitors
PCT/GB1996/001093 WO1996034890A2 (en) 1995-05-05 1996-05-07 Inhibitors of fibrin cross-linking and/or transglutaminases

Publications (2)

Publication Number Publication Date
NO975080D0 NO975080D0 (no) 1997-11-04
NO975080L true NO975080L (no) 1998-01-02

Family

ID=10774108

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975080A NO975080L (no) 1995-05-05 1997-11-04 Inhibitorer av fibrintverrbinding og/eller transglutaminaser

Country Status (14)

Country Link
US (1) US6025330A (no)
EP (1) EP0848719A2 (no)
JP (1) JPH11505218A (no)
KR (1) KR19990008348A (no)
AU (1) AU723130B2 (no)
BR (1) BR9608207A (no)
CA (1) CA2220268A1 (no)
CZ (1) CZ348197A3 (no)
GB (1) GB9509271D0 (no)
HU (1) HUP9900408A3 (no)
NO (1) NO975080L (no)
PL (1) PL323252A1 (no)
SK (1) SK148797A3 (no)
WO (1) WO1996034890A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056409A1 (en) * 1997-06-11 1998-12-17 Smithkline Beecham Corporation USE OF FACTOR XIIIa INHIBITORS TO TREAT ATHEROSCLEROSIS
DE10046187A1 (de) * 2000-09-13 2002-03-21 Univ Schiller Jena Verfahren zur Messung der Aktivität von Gerinnungsfaktor XIIIa
DE10163333B4 (de) * 2001-12-21 2007-01-25 Curacyte Ag Modifizierte Tridegine, ihre Herstellung deren Verwendung als Transglutaminase Inhibitoren und diese enthaltende Arzneimittel und Kombinationspräparate
JP2005513141A (ja) * 2001-12-21 2005-05-12 キュラサイト・アクチェンゲゼルシャフト 修飾トリデジン（ｔｒｉｄｅｇｉｎｓ）、その製剤、およびトランスグルタミナーゼ阻害剤としてのその使用
US20110034396A1 (en) * 2005-09-28 2011-02-10 Biovascular, Inc. Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
EP1931733A4 (en) * 2005-09-28 2009-11-25 Biovascular Inc METHOD AND COMPOSITIONS FOR BLOCKING THROMBOZYTE AND CELL ADHESION, CELL MIGRATION AND IGNITION
US20100316764A1 (en) * 2009-06-10 2010-12-16 Engrain, LLC Flour supplement compositions and methods for preparing wheat flour
GB201318182D0 (en) * 2013-10-14 2013-11-27 Univ Nottingham Trent Inhibitor peptides
KR102131041B1 (ko) 2013-12-03 2020-07-08 (주)아모레퍼시픽 태양광 차단 기능성 물질 스크리닝 방법 및 태양광 차단 효능 평가 방법
WO2017089961A1 (pt) * 2015-11-24 2017-06-01 Universidade De Trás-Os-Montes E Alto Douro Método para a produção de farinhas de cereais e de proteínas enriquecidas em l-teanina e respectivos produtos
TWI825144B (zh) 2018-08-10 2023-12-11 美商思達利醫藥公司 第二型轉麩醯胺酸酶(tg2)抑制劑
CN110174513A (zh) * 2019-04-15 2019-08-27 中山大学附属第一医院 Tgm2在制备监测克罗恩病疾病活动的生物标志物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052062T3 (es) * 1988-06-11 1994-07-01 Ciba Geigy Ag Nuevos polipeptidos con actividad anticoagulante.
US5227469A (en) * 1990-02-14 1993-07-13 Genentech, Inc. Platelet aggregation inhibitors from the leech
US5328898A (en) * 1990-06-22 1994-07-12 Duke University Factor XIIIA fibrin binding fragments
AU1436292A (en) * 1991-02-11 1992-09-07 Medicis Corporation Transglutaminase enzyme inhibitors
IT1264084B1 (it) * 1993-12-22 1996-09-10 Raggio Italgene Spa Peptide ad attivita' di substrato e/o inibitore dell'enzima transglutaminasi e suo uso in diagnosi e terapia.
DE4402631A1 (de) * 1994-01-29 1995-08-03 Boehringer Mannheim Gmbh Verfahren zur Bestimmung von Gerinnungsparametern

Also Published As

Publication number Publication date
HUP9900408A2 (hu) 1999-05-28
US6025330A (en) 2000-02-15
AU723130B2 (en) 2000-08-17
EP0848719A2 (en) 1998-06-24
SK148797A3 (en) 1998-04-08
CA2220268A1 (en) 1996-11-07
JPH11505218A (ja) 1999-05-18
KR19990008348A (ko) 1999-01-25
WO1996034890A2 (en) 1996-11-07
PL323252A1 (en) 1998-03-16
CZ348197A3 (cs) 1998-03-18
AU5654696A (en) 1996-11-21
WO1996034890A3 (en) 1997-10-23
NO975080D0 (no) 1997-11-04
BR9608207A (pt) 2000-10-31
GB9509271D0 (en) 1995-06-28
HUP9900408A3 (en) 2001-10-29
MX9708513A (es) 1998-08-30

Similar Documents

Publication Publication Date Title
NO975080L (no) Inhibitorer av fibrintverrbinding og/eller transglutaminaser
Laato et al. Stimulation of wound healing by epidermal growth factor. A dose-dependent effect.
DE69430315D1 (de) Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl
NO20006078L (no) N-bundete sulfen-amider av N-heterocykliske karboksylsyrer eller karboksylsyre-isostere
UA84665C2 (ru) Способ ингибирования опосредствованного ангиогенеза в ткани у пациента с неоваскулярным заболеванием роговицы
DE69324151D1 (de) Inhibitoren des arginin-ketoamid-enzyms
WO2002002593A3 (en) Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
JPH04211019A (ja) 創傷治癒促進のためのトロンボスポンデインの使用
ES2129426T3 (es) Polipeptidos antitrombinicos.
EA200001124A1 (ru) Способ генной терапии
ATE359798T1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
NO974260L (no) Nye definerte enzymblandinger for oppnåelse av celler og behandling av sår
RU2002135669A (ru) Олигопептиды
ATE369856T1 (de) Verfahren zur behandlung von glaukom
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
Collier LXIV The Present Position of Facial Nerve Surgery
Peacock Collagenolysis: The other side of the equation
NO980300L (no) Nye höymolekylære humane MP52 proteiner
NO995692D0 (no) Nye BPC-peptidsalter med organbeskyttende aktivitet, metoden for deres fremstilling og deres anvendelse
ATE374048T1 (de) Verwendung von matrixprotein für gesteuerte geweberegenerationen
US6340458B1 (en) Use of enzymes for skin expansion
ATE319740T1 (de) Verfahren zur gewinnung und anwendung von antibiotisch wirksamen peptiden zur behandlung von infektionskrankheiten
RU2192814C1 (ru) Способ лечения эпителиальных ран роговицы
ATE203680T1 (de) Konjugat zur behandlung von entzündungserkrankungen
ATE252902T1 (de) Verwendung von calciumkanalanantagonisten zur behandlung von herz-, nieren-, magen-und darmkrankheiten sowie bluthochdruck

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application